Syros Pharmaceuticals Stock News

Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, inc

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.55% and 38.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Syros Pharmaceuticals (NASDAQ: SYRS ) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Syros Pharmaceuticals beat estimated earnings by 19.15%, reporting an EPS of $-0.38 versus … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph

Syros Pharmaceuticals press release (SYRS): Q4 GAAP EPS of -$0.38 beats by $0.08.Revenue of $78M (+1268.4% Y/Y) beats by $73.16M.Cash, cash equivalents and marketable securities as…

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 4.55% and 38.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ: IDYA ) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi Trends (NASDAQ: CTRN ) is projected to report quarterly earnings at $1.12 per share on revenue of $250.54 million. • Precision BioSciences (NASDAQ: DTIL ) is likely to report quarterly loss at $0.47 per share on revenue of $7.75 million. • SPX FLOW (NYSE: FLOW ) is estimated to report quarterly loss at $0.17 per share on revenue of $10.88 million. • Brickell Biotech (NASDAQ: BBI ) is likely to report quarterly loss at $0.08 per share on revenue of $150.00 thousand. • Imara (NASDAQ: IMRA ) is expected to report earnings for its fourth quarter. • Gamida Cell (NASDAQ: GMDA ) is estimated to report earnings for its fourth quarter. • Syros Pharmaceuticals (NASDAQ: SYRS ) is likely to report quarterly loss at $0.47 per share on revenue of $4.80 million. • Global X Guru Index ETF (NYSE: GURU ) is likely to report quarterly loss at $0.

Syros Pharmaceuticals (NASDAQ:SYRS) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open.The consensus EPS Estimate is -$0.45 (+27.4% Y/Y) and…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, March 15, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update. To access the live conference call, please dial (866) 595-4538 (domestic) or (636) 812-6496 (international) and refer to conference ID 968

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new preclini

Intercept (ICPT) delivered earnings and revenue surprises of 2.38% and 0.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -21.28% and 11.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1.49% and 10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st